



Current Agreements

Dealdoc

Contract service agreement for MyHeart platform

Novoheart

Jan 30 2018

Contract service agreement for MyHeart platform

| | |
|---------------------------|---------------------------|
| Companies: | Novoheart |
| Announcement date: | Jan 30 2018 |
| Deal value, US\$m: | n/d |

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

| | |
|---------------------------|--|
| Announcement date: | Jan 30 2018 |
| Industry sectors: | Pharmaceutical Services |
| Asset type: | Technology |
| Therapy areas: | Cardiovascular |
| Technology types: | Enabling technology Research services |
| Deal components: | Contract service |

Financials

| | |
|---------------------------|-----|
| Deal value, US\$m: | n/d |
|---------------------------|-----|

Termsheet

Novoheart announced the successful completion of a second commercial contract with a major global pharma partner.

The second contract was initiated after a successful initial collaboration that validated the drug screening capabilities of Novoheart's proprietary MyHeart Platform.

In the latest study, Novoheart successfully designed and generated engineered human heart cells, tissues and chambers that carried a hereditary mutation responsible for a neurological disorder with cardiac dysfunction being the most frequent cause of death, in over two thirds of the afflicted individuals.

The various disease-specific heart constructs are then used as the only human heart tissue models available for testing novel therapeutic candidates that target the disease.

Novoheart has retained ownership of intellectual property generated from the project.

A joint scientific report is currently being finalized by both parties, and will be submitted for publication in a peer-reviewed scientific journal.

Novoheart is to receive payment from the Pharma within 60 days of the project's completion.

This income will be reflected in its Q2 financial statement.

Further details will be announced separately.

Press Release

Novoheart Announces Successful Completion of Second Commercial Contract with Global Pharmaceutical Company

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- Jan 30, 2018 -- Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH) is pleased to announce the successful completion of a second commercial contract with a major global pharma partner (Pharma). The second contract was initiated after a successful initial collaboration that validated the drug screening capabilities of Novoheart's proprietary MyHeart™ Platform.

In the latest study, Novoheart successfully designed and generated engineered human heart cells, tissues and chambers that carried a hereditary mutation responsible for a neurological disorder with cardiac dysfunction being the most frequent cause of death, in over two thirds of the afflicted individuals. The various disease-specific heart constructs are then used as the only human heart tissue models available for testing novel therapeutic candidates that target the disease.

"This is a significant upgrade for drug discovery, because previous genetic mouse models cannot reproduce certain key features of this human condition," said Novoheart CEO Ronald Li.

Under the agreement, Novoheart has retained ownership of intellectual property generated from the project. A joint scientific report is currently being finalized by both parties, and will be submitted for publication in a peer-reviewed scientific journal.

Novoheart is to receive payment from the Pharma within 60 days of the project's completion. This income will be reflected in its Q2 financial statement. Further details will be announced separately.

About Novoheart:

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.

Also known as 'human heart-in-a-jar', Novoheart's bioartificial human heart constructs are created using state-of-the-art stem cell and bioengineering approaches, and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

The Company is listed on the TSX Venture Exchange (the "TSXV") under the symbol "NVH".

Filing Data

Not available.

Contract

Not available.